NCT05971628

Brief Summary

This is a national, non-randomized, multicentric trial evaluating the feasibility and the tolerance of the RAPID procedure in patients with HCC with preserved liver function requiring a liver transplantation.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable hepatocellular-carcinoma

Timeline
37mo left

Started Sep 2023

Longer than P75 for not_applicable hepatocellular-carcinoma

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Sep 2023Jun 2029

First Submitted

Initial submission to the registry

June 30, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 2, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2027

Expected
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2029

Last Updated

August 2, 2023

Status Verified

June 1, 2023

Enrollment Period

4.1 years

First QC Date

June 30, 2023

Last Update Submit

July 24, 2023

Conditions

Keywords

liver transplantationsplitauxiliary transplantationHepatocellular Carcinoma

Outcome Measures

Primary Outcomes (2)

  • Proportion of patient with successful RAPID procedure

    Success of the procedure will be assessed as a patient : * who complete the 2 steps of the procedure, * who had no graft resection and who is still alive 4 months later.

    4 months after the second RAPID step

  • Tolerance of the RAPID procedure

    Tolerance will be assessed with Adverse events related to the procedure

    from first stage of the surgical protocol and until 90 days after the second stage

Secondary Outcomes (10)

  • Proportion of grafts in place

    4 months after the first surgical step

  • Survival of grafts at 2 years from liver transplantation (LT)

    at 2 Years from LT

  • Survival of patient at 2 year after their registration on the waiting list of transplantation

    at 2 year after their registration on the waiting list of transplantation

  • Survival of patient at 2 year after LT

    at 2 year after LT

  • Incidence of rejection after RAPID

    at 2 years after the first stage of RAPID

  • +5 more secondary outcomes

Study Arms (2)

Liver transplantation with the RAPID procedure

EXPERIMENTAL

Liver transplantation for hepatocellular carcinoma according to the RAPID protocol. This protocol is an auxiliary liver transplantation of a partial graft with total hepatectomy in two stages (2 successive operations).

Procedure: RAPID procedure

Comparator group with standard liver transplantation (whole graft)

NO INTERVENTION

Orthotopic liver transplantation with whole organ from deceased donor for hepatocellular carcinoma. Data will be provided by Biomedicine Agency, following pairing rules.

Interventions

RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma

Liver transplantation with the RAPID procedure

Eligibility Criteria

Age18 Years - 68 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years ≤ age ≤ 68 years
  • Indication of LT for HCC validated in multidisciplinary meeting
  • AFP score ≤ 2 (15)
  • Body mass index \< 30 kg/m2
  • MELD score ≤ 15, without access to prioritization
  • PET CT-choline and PET CT-FDG without sign of extra-hepatic localizaton
  • Patient having been informed and able to give written consent to participate in the RAPID-HCC study

You may not qualify if:

  • History of, liver transplant, surgical or radiological portocaval anastomosis
  • History of major abdominal surgery (including hepatectomy)
  • History of abdominal radiotherapy (extrahepatic)
  • History of acute/chronic pancreatitis
  • Expected combined transplant
  • HCC located 1 cm away from the transection line required by the first stage hepatectomy
  • Portal or arterial thrombosis
  • patient with a pre-graft hepatic venous pressure gradient ≥ 20mmHg
  • Ascites (clinical or radiological) less than 5 years ago
  • Hepatitis C viral load +
  • Acute or chronic hepatitis B (not cured)
  • HIV + serology
  • Severe comorbidities, in particular severe cardiovascular or respiratory or renal pathology (at the discretion of the medical-surgical team)
  • Patient on anticoagulant treatment
  • Patient who has received (or is due to receive) preoperative treatment with radioembolization on the right side, hepatectomy or radiotherapy near the hilum
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AP-HP, Paul Brousse Hospital

Villejuif, 94800, France

Location

Related Publications (1)

  • Peloso A, Pietrasz D, Daillier E, Cylly L, Scatton O, Goumard C, Mabrut JY, Mohkam K, Lesurtel M, Dokmak S, Jeddou H, Boudjema K, Allard MA, Adam R, Sa Cunha A, Azoulay D, Cherqui D, Vibert E, Golse N. Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial. BMC Cancer. 2025 May 9;25(1):848. doi: 10.1186/s12885-025-14127-7.

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

  • Nicolas GOLSE, Doctor

    APHP, Paul Brousse Hospital, villejuif, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nicolas GOLSE, Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2023

First Posted

August 2, 2023

Study Start

September 1, 2023

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

June 1, 2029

Last Updated

August 2, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations